Galapagos (GB:0JXZ) has released an update.
Galapagos advances its ‘Forward, Faster’ strategy, posting positive half-year 2024 financials and making strides in cell therapy with IND and CTA submissions for pivotal CAR-T studies in cancer treatment. The company’s robust pipeline includes over 15 preclinical programs and a strong cash position, with reaffirmed 2024 outlook and cash burn guidance. Strategic partnerships bolster Galapagos’ U.S. manufacturing expansion and solid tumor treatment options.
For further insights into GB:0JXZ stock, check out TipRanks’ Stock Analysis page.
